These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 19440560)

  • 61. India's pharmaceutical industry: hype or high tech take-off?
    Malhotra P; Lofgren H
    Aust Health Rev; 2004 Nov; 28(2):182-93. PubMed ID: 15527398
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmaceutical policy in Italy: towards a structural change?
    Ghislandi S; Krulichova I; Garattini L
    Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
    [TBL] [Abstract][Full Text] [Related]  

  • 63. IP litigation in China could drive innovation.
    Jia H
    Nat Biotechnol; 2004 Apr; 22(4):368. PubMed ID: 15060539
    [No Abstract]   [Full Text] [Related]  

  • 64. India: access to affordable drugs and the right to health.
    Grover A; Citro B
    Lancet; 2011 Mar; 377(9770):976-7. PubMed ID: 21227487
    [No Abstract]   [Full Text] [Related]  

  • 65. [Patients, patents and profits].
    Roland PC
    Tidsskr Nor Laegeforen; 2008 Jan; 128(2):205. PubMed ID: 18202741
    [No Abstract]   [Full Text] [Related]  

  • 66. Regulators can challenge deals that delay generic competition, says US Supreme Court.
    McCarthy M
    BMJ; 2013 Jun; 346():f3964. PubMed ID: 23783361
    [No Abstract]   [Full Text] [Related]  

  • 67. Patent Cliffs in the Era of Complex Therapies and Biologics.
    Sabatini MT; Silva M
    Pharmaceut Med; 2020 Aug; 34(4):271-278. PubMed ID: 32772314
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
    Sarpatwari A; Kesselheim AS
    PLoS Med; 2016 Feb; 13(2):e1001955. PubMed ID: 26859662
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Possible anticompetitive agreements between brand, generic companies to be studied.
    Landis NT
    Am J Health Syst Pharm; 2000 Dec; 57(23):2140, 2142. PubMed ID: 11127691
    [No Abstract]   [Full Text] [Related]  

  • 70. A Method for Approximating Future Entry of Generic Drugs.
    Beall RF; Darrow JJ; Kesselheim AS
    Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Are patent expirations the answer to improving patient adherence?
    Klepser DG
    Am J Manag Care; 2008 Dec; 14(12):787-8. PubMed ID: 19067495
    [No Abstract]   [Full Text] [Related]  

  • 72. Statin utilisation--recognising the role of the invisible hand.
    Minhas R
    Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171
    [No Abstract]   [Full Text] [Related]  

  • 73. Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study.
    Lexchin J
    Value Health; 2017 Sep; 20(8):1139-1142. PubMed ID: 28964446
    [TBL] [Abstract][Full Text] [Related]  

  • 74. GSK paid smaller companies to delay generic versions of paroxetine, says fair trade body.
    Dyer C
    BMJ; 2013 Apr; 346():f2566. PubMed ID: 23610379
    [No Abstract]   [Full Text] [Related]  

  • 75. [The patent is "engine" in drug development].
    Bergström R
    Lakartidningen; 2008 Mar 5-11; 105(10):752. PubMed ID: 18422246
    [No Abstract]   [Full Text] [Related]  

  • 76. Reinventing an industry.
    Mandavilli A
    Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
    [No Abstract]   [Full Text] [Related]  

  • 77. Current trends in the pharmaceutical industry--a case study approach.
    Rusu A; Kuokkanen K; Heier A
    Eur J Pharm Sci; 2011 Oct; 44(3):437-40. PubMed ID: 21782941
    [TBL] [Abstract][Full Text] [Related]  

  • 78. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 2.
    Kuhrt K
    IDrugs; 2009 Dec; 12(12):765-9. PubMed ID: 19943218
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Impact of the introduction of mandatory generic substitution in South Africa: private sector sales of generic and originator medicines for chronic diseases.
    Gray AL; Santa-Ana-Tellez Y; J Wirtz V
    Trop Med Int Health; 2016 Dec; 21(12):1504-1512. PubMed ID: 27671539
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The diffusion of generics after patent expiry in Germany.
    Fischer KE; Stargardt T
    Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.